Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20994722 | 0.98 | TLR8 (0.39) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL19582677 | 0.95 | L3MBTL1 (0.40) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL19087084 | 0.92 | TLR8 (0.41) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL21024640 | 0.92 | TLR8 (0.41) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL27895992 | 0.92 | TLR8 (0.41) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL20372906 | 0.92 | TLR8 (0.41) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL20098274 | 0.90 | TLR8 (0.40) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL28717092 | 0.90 | TLR8 (0.40) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL28717680 | 0.89 | TLR8 (0.41) | TLR8L3MBTL1ALDH1A1POLBKMT2A | |
| SCHEMBL14148932 | 0.84 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4650498-A1 | FLUID CONTACTING DEVICE | Aurotec GmbH (AT) | 2025-11-19 | — | — | EP | claimed |
| US-7858802-B2 | Method of preparing ionic liquids | BASF SE (DE) | 2010-12-28 | — | — | US | claimed |
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | COVESTRO DEUTSCHLAND AG (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-4650498-A1 | FLUID CONTACTING DEVICE | Aurotec GmbH (AT) | 2025-11-19 | — | — | EP | disclosed |
| EP-4157912-B1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-22 | — | — | EP | disclosed |
| EP-3997183-B1 | METHOD FOR THE PRODUCTION OF ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230192941-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4157912-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | Covestro Deutschland AG (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20220348708-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20220251280-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-08-11 | — | — | US | disclosed |
| CN-1914181-A | Method for preparing ionic liquid | BASF AG (DE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1711472-A1 | MEHTOD FOR PRODUCING IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-18 | — | — | EP | disclosed |
| CN-1826326-A | Method for the production of purified 1,3-substituted imidazolium salts | BASF AG (DE) | 2006-08-30 | — | — | CN | disclosed |
| CN-1826302-A | Method for extracting impurities using ionic liquids | BASF AG (DE) | 2006-08-30 | — | — | CN | disclosed |
| US-20060149074-A1 | Method for the production of purified 1,3-substituted imidazolium salts | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1648845-A1 | METHOD FOR EXTRACTING IMPURITIES USING IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005070896-A1 | MEHTOD FOR PRODUCING IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005019137-A1 | METHOD FOR EXTRACTING IMPURITIES USING IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | WO | disclosed |
| EP-1398318-A1 | Process for conducting chemical reactions in a liquid phase in the presence of a catalyst and a 1,3-substituted imidazolium salt | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559586-B2 | Compositions containing uretdione groups crosslinking at low temperatures | URB2, UQCRB, UQCRC2 | TLR8 4009/4885L3MBTL1 3338/4885ALDH1A1 1357/4885 |
| US-20060149074-A1 | Method for the production of purified 1,3-substituted imidazolium salts | HIRA, HAO2, HACL2 | TLR8 4532/4885L3MBTL1 4844/4885ALDH1A1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.